Suppr
超能文献

Reply: NOAC Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.

作者信息

Yao Xiaoxi, Shah Nilay D, Sangaralingham Lindsey R, Gersh Bernard J, Noseworthy Peter A

出版信息

J Am Coll Cardiol. 2017 Nov 28;70(21):2734-2735. doi: 10.1016/j.jacc.2017.09.1092.

DOI:10.1016/j.jacc.2017.09.1092

PMID:29169488

Abstract

摘要

相似文献

Reply: NOAC Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.

J Am Coll Cardiol. 2017 Nov 28;70(21):2734-2735. doi: 10.1016/j.jacc.2017.09.1092.

NOAC Dosing in Atrial Fibrillation and Renal Dysfunction: What Measure Are You Using?

J Am Coll Cardiol. 2017 Nov 28;70(21):2733-2734. doi: 10.1016/j.jacc.2017.09.1091.

Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.

Cardiol Rev. 2016 Sep-Oct;24(5):218-23. doi: 10.1097/CRD.0000000000000088.

Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae.

Can J Cardiol. 2018 Aug;34(8):1010-1018. doi: 10.1016/j.cjca.2018.04.019. Epub 2018 Apr 25.

Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).

Am J Cardiol. 2017 May 15;119(10):1590-1595. doi: 10.1016/j.amjcard.2017.02.015. Epub 2017 Mar 28.

Novel oral anticoagulants for atrial fibrillation.

Singapore Med J. 2015 Dec;56(12):657-8; quiz 659. doi: 10.11622/smedj.2015184.

Treatment Changes among Users of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

Basic Clin Pharmacol Toxicol. 2017 Feb;120(2):187-194. doi: 10.1111/bcpt.12664. Epub 2016 Oct 28.

Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.

Thromb Haemost. 2014 May 5;111(5):808-16. doi: 10.1160/TH13-09-0741. Epub 2013 Nov 28.

Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.

Ir J Med Sci. 2019 Feb;188(1):101-108. doi: 10.1007/s11845-018-1837-7. Epub 2018 Jun 2.

Kidney function monitoring and nonvitamin K oral anticoagulant dosage in atrial fibrillation.

Eur J Clin Invest. 2018 Jun;48(6):e12907. doi: 10.1111/eci.12907. Epub 2018 Apr 22.

引用本文的文献

Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses.

BMC Cardiovasc Disord. 2020 Feb 3;20(1):42. doi: 10.1186/s12872-020-01340-4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Reply: NOAC Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译